Log in

NYSEAMERICAN:IBIOIbio Stock Price, Forecast & News

$2.22
-0.06 (-2.63 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.11
Now: $2.22
$2.25
50-Day Range N/A
52-Week Range
$0.05
Now: $2.22
$3.40
Volume6.88 million shs
Average Volume20.96 million shs
Market Capitalization$262.76 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.12 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:IBIO
Previous SymbolNASDAQ:IBIO
CUSIPN/A
Phone+1-302-3550650

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees54
Market Cap$262.76 million
Next Earnings Date8/21/2020 (Estimated)
OptionableNot Optionable

Receive IBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter.

Ibio (NYSEAMERICAN:IBIO) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Ibio?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ibio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ibio.

When is Ibio's next earnings date?

Ibio is scheduled to release its next quarterly earnings announcement on Friday, August 21st 2020. View our earnings forecast for Ibio.

When did Ibio's stock split? How did Ibio's stock split work?

Ibio shares reverse split on the morning of Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 8th 2018. An investor that had 100 shares of Ibio stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for IBIO?

1 brokers have issued 12 month price objectives for Ibio's stock. Their forecasts range from $2.55 to $2.55. On average, they anticipate Ibio's stock price to reach $2.55 in the next year. This suggests a possible upside of 14.9% from the stock's current price. View analysts' price targets for Ibio.

Has Ibio been receiving favorable news coverage?

Media stories about IBIO stock have trended very negative on Sunday, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ibio earned a coverage optimism score of -3.2 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Ibio.

Who are some of Ibio's key competitors?

What other stocks do shareholders of Ibio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ibio investors own include Inovio Pharmaceuticals (INO), Co-Diagnostics (CODX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Novavax (NVAX), Nokia Oyj (NOK), Biocept (BIOC), FuelCell Energy (FCEL) and Gilead Sciences (GILD).

Who are Ibio's key executives?

Ibio's management team includes the following people:
  • Mr. Robert B. Kay, Exec. Chairman & CEO (Age 79)
  • Mr. Robert L. Erwin, Pres (Age 66)
  • Mr. James P. Mullaney CPA, CPA, Chief Financial Officer (Age 48)
  • Mr. Terence E. Ryan, Chief Scientific Officer (Age 64)
  • Dr. Renato Lobo, Chief Medical Officer

What is Ibio's stock symbol?

Ibio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

How do I buy shares of Ibio?

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ibio's stock price today?

One share of IBIO stock can currently be purchased for approximately $2.22.

How big of a company is Ibio?

Ibio has a market capitalization of $262.76 million. Ibio employs 54 workers across the globe.

What is Ibio's official website?

The official website for Ibio is www.ibioinc.com.

How can I contact Ibio?

Ibio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at +1-302-3550650.

This page was last updated on 7/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.